J B CHEMICALS AND PHARMA

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on February 09, 2018.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 09, 2018, titled "Press Release".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Dear Sir,Sub: EU approval for manufacturing facilities at Panoli This is to inform you that Medicines Authority of Malta has accorded its approval to the Company��s manufacturing facilities at Panoli, Gujarat for tablets, capsules, liquids for internal use and semi-solids (i.e. topical preparations like Ointments, Creams and Gels). This approval is valid in entire European Union. This approval will not only help Company increase its product basket for this market but will also boost contra

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 17, 2018, titled "Press Release".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Supplementary ANDA approval by US FDA '.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2017.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 10, 2017, titled "Press Release ".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 19, 2017. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Change in Auditors of the company.

The company had informed the Exchange that the Register of Members and Share Transfer Books will remain closed from September 13, 2017 to September 19, 2017 (both days inclusive) To ascertain eligibility of the beneficial owners/ shareholders for dividend for FY 2016-17, if declared at the Annual General Meeting. The company has now inform the exchange that the Register of Members and Share Transfer Books will remain closed from September 13, 2017 to September 19, 2017 (both days inclusive) for the purpose of AGM and Dividend.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Register of Members and Share Transfer Books will remain closed from September 13, 2017 to September 19, 2017 (both days inclusive) To ascertain eligibility of the beneficial owners/ shareholders for dividend for FY 2016-17, if declared at the Annual General Meeting

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 19, 2017

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the company has fixed September 12, 2017 as cut off date to ascertain eligibility of the beneficial owners/shareholders of the Company's share to receive the dividend for FY 2016-17, if declared at the annual general Meeting.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Date of payment of dividend

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 11, 2017, titled "Press Release".

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended June 30, 2017.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange a copy of post Buy-Back Announcement for the attention of equity shareholders / beneficial owners of equity shares of J.B. Chemicals & Pharmaceuticals Limited

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of . Revised Standalone audited financial results for the year ended on March 31, 2017 alongwith Auditor s Report. an Consolidated audited financial results for the year ended on March 31, 2017 alongwith Auditor s Report,

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of Public Announcement Buy-back of Equity Shares of the Company .

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Filing of copy of Board Resolution pursuant to the provisions of SEBI (Buy-Back of Securities) Regulation, 1998 ( said Regulations ).

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Declaration for audit reports with unmodified opinion(s).

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has fixed Record Date as June 2, 2017 for the purpose of to determine the entitlement and names of Equity Shareholders, who shall be entitled to participate in the proposed offer for Buy-back of up to 12,50,000 Equity Shares of the Company at the price of Rs.400/- per Equity Share.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company has, at its meeting held on May 23, 2017 approved the Buy-back of up to 12,50,000 fully paid up Equity Shares of face value of Rs. 2/- each by the Company (representing 1.47% of the total paid up Equity Share capital of the Company) at a price of Rs.400/- (Rupees four hundred) per Equity Share payable in cash for a total consideration not exceeding Rs. 50/- crores (Rupees fifty crores only) (excluding transaction costs such as fees, brokerage, taxes, duties, etc), which is not exceeding

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 23, 2017, has recommended a dividend of Re.1 (50%) per equity share of FV of Rs.2 for the year 2016-17. The dividend if declared, will be paid/ despatched on September 1, 2017.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 23, 2017, titled "Press Release".

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2017.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of Notice in respect of transfer of equity shares of the Company to Investor Education and Protection Fund (IEPF).

J B Mody, D B Mody and S B Mody has submitted to the Exchange vide letter dated April 04, 2017 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per Company s code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in the securities of the Company will remain closed from April 1, 2017 and will re-open on May 29, 2017 in connection with consideration and approval of the audited accounts for the financial year ending on March 31, 2017 by the Board of Directors of the Company.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 10, 2017, titled "StockExchange-NSE letters/MM:SA:660 February 10, 2017National Stock Exchange of India LimitedExchange PlazaBandra Kurla ComplexBandra (E), Mumbai 400 051Stock Symbol: JBCHEPHARMDear Sir,Sub : Press Release Enclosed is a press release we propose to issue on unaudited financial results for the quarter ended on December 31, 2016.Kindly take the same on record.Thanking you, Yours faithfully, for J.B. Chemicals & Pharmaceuticals LimitedM. C

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2016.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per Company s code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in the securities of the Company will remain closed from January 1, 2017 and will re-open on February 15, 2017 in connection with consideration and approval of unaudited financial results for the quarter ending on December 31, 2016 by the Board of Directors of the Company.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Dr. Niranjan N. Maniar, independent director of the Company, has resigned from the Board of directors of the Company with immediate effect due to his health problems.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2016.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on November 18, 2016, appointed Sr. Manoj R. Mashru as Additional director of the Company. he is an independent director on the Board.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 18, 2016, titled "Press Release".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Corporate office and future Communication address of the Company now is as under: J. B. CHEMICALS & PHARMACEUTICALS LIMITED Cnergy IT Park, Unit A2, 3rd Floor, Appa Saheb Marathe Marg, Prabhadevi Mumbai 400 025 Phone: +91 22 2439 5200 / 2439 5500

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per Companys code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in the securities of the Company will remain closed from October 1, 2016 and will re-open on November 23, 2016 in connection with consideration and approval of unaudited financial results for the quarter ending on September 30, 2016 by the Board of Directors of the Company.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Mr. Jashvantrai Joshi, Independent Director of the Company, has resigned from the Board of Directors of the Company effective from September 29, 2016 due to his inability to devote necessary time to his duty as independent director of the Company.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding "Schedule of meeting with analyst/institutional investor".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 26, 2016 titled "Unaudited Financial Results for Q1 - 2016-17".

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended June 30, 2016.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on the August 23, 2016 along with Report of Scrutinizer.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on August 23, 2016.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on August 23, 2016.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from August 16, 2016 to August 23, 2016 (both days inclusive) for the purpose to ascertain eligibility of the beneficial owners / shareholders for final dividend for FY 2015-16, if declared at the annual general meeting.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a Copy of Notice of Annual General Meeting of the Company to be held on August 23, 2016.